指南与共识糖尿病肥胖与代谢综合征

1型糖尿病儿童和青少年高胆固醇血症与降脂治疗:我们是否落实了现行指南?

Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?
指南 / 共识 · Diabetes Care · 2026-01-01

基于德国DPV注册库2013–2023年数据,纳入55,028例18岁以下1型糖尿病患儿,评估LDL升高患病率、降脂药物使用及达标情况。结果显示9.7%和2.3%的患儿LDL分别>3.4和>4.1 mmol/L,仅7.3%的LDL升高者接受降脂药物治疗,且治疗者中仅15.7%达到LDL<2.6 mmol/L的目标。

要点

  • 1型糖尿病患儿中LDL>3.4 mmol/L者占9.7%,>4.1 mmol/L者占2.3%。
  • LDL升高患儿中仅7.3%接受降脂药物治疗,多数有治疗指征者未治疗。
  • 接受治疗者中仅15.7%达到LDL<2.6 mmol/L目标,55%仍>3.4 mmol/L。

核心结论

  • 1型糖尿病患儿中LDL高胆固醇血症患病率高,降脂药物使用率低且治疗达标率低,血脂异常仍是儿科糖尿病中被低估的心血管危险因素。

研究设计与样本

  • 基于德国糖尿病前瞻性随访注册库(DPV)2013–2023年数据的横断面分析,纳入18岁以下1型糖尿病且至少有一次LDL检测记录的患儿55,028例。

主要发现

  • 9.7%的患儿LDL>3.4 mmol/L,2.3%的患儿LDL>4.1 mmol/L。
  • HbA1c(β=1,142.7;P=0.001)、女性(β=861.5;P<0.001)和BMI>第70百分位(β=520.1;P<0.001)对LDL水平影响最强。
  • LDL升高患儿中仅7.3%接受降脂药物治疗;LDL>3.4 mmol/L者中92.7%未治疗,LDL>4.1 mmol/L者中87.0%未治疗。
  • 接受降脂治疗的患者(n=707)中仅15.7%达到LDL<2.6 mmol/L目标,55%的LDL仍>3.4 mmol/L。

关键数值与推荐

  • LDL切点定义为>2.6、>3.4和>4.1 mmol/L。
  • 使用降脂药物的估计比值比(95%CI):LDL>4.1 mmol/L为19.13(15.4-23.7);年龄12-18岁为3.1(1.82-5.41);糖尿病病程5-10年为2.31(1.9-2.1);BMI>第70百分位为1.8(1.5-2.1);HbA1c>9%为1.3(1.0-1.6);女性为1.18(1.0-1.4)。

临床怎么用

  • 对1型糖尿病患儿应常规筛查LDL,尤其关注HbA1c高、女性及BMI>第70百分位者。
  • 有治疗指征的LDL升高患儿应积极启动降脂药物,并评估剂量依从性以促进达标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values. RESEARCH DESIGN AND METHODS: A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age <18 years, and at least one documented LDL measurement. LDL cutoffs of >2.6, >3.4, and >4.1 mmol/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4. RESULTS: The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL >3.4 mmol/L and >4.1 mmol/L, respectively. The parameters HbA1c (β = 1,142.7; P = 0.001), female sex (β = 861.5; P < 0.001), and BMI >70th percentile (β = 520.1; P < 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL >3.4 mmol/L and 87.0% with LDL >4.1 mmol/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4-23.7) for LDL >4.1 mmol/L; 3.1 (1.82-5.41) for ages 12-18 years; 2.31 (1.9-2.1) for diabetes duration of 5-10 years; 1.8 (1.5-2.1) for BMI >70th percentile; 1.3 (1.0-1.6) for HbA1c >9%; and 1.18 (1.0-1.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of <2.6 mmol/L, and LDL levels of 55% even remained at >3.4 mmol/L. CONCLUSIONS: We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Weiskorn J, Becker M, Kamrath C, et al. Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines? Diabetes Care. 2026. PMID: 41842727. doi:10.2337/dc25-2459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。